436 related articles for article (PubMed ID: 17158352)
1. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
Muldowney JA; Stringham JR; Levy SE; Gleaves LA; Eren M; Piana RN; Vaughan DE
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):400-6. PubMed ID: 17158352
[TBL] [Abstract][Full Text] [Related]
2. Emerging thrombotic effects of drug eluting stents.
Lang NN; Newby DE
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):261-2. PubMed ID: 17229968
[No Abstract] [Full Text] [Related]
3. Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents.
Ma Q; Zhou Y; Nie X; Yu M; Gao F; Wang Z; Ge H; Jia D; Yang S; Liu X; Han H; Hu B; Shen H; Xu X
Angiology; 2012 Jul; 63(5):330-5. PubMed ID: 21900343
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design.
Steffel J; Latini RA; Akhmedov A; Zimmermann D; Zimmerling P; Lüscher TF; Tanner FC
Circulation; 2005 Sep; 112(13):2002-11. PubMed ID: 16172265
[TBL] [Abstract][Full Text] [Related]
5. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
[TBL] [Abstract][Full Text] [Related]
7. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
Zhao FH; Chen YD; Jin ZN; Lu SZ
Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
Parry TJ; Brosius R; Thyagarajan R; Carter D; Argentieri D; Falotico R; Siekierka J
Eur J Pharmacol; 2005 Nov; 524(1-3):19-29. PubMed ID: 16271360
[TBL] [Abstract][Full Text] [Related]
9. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells.
Midorikawa S; Sanada H; Hashimoto S; Watanabe T
Biochem Biophys Res Commun; 2000 May; 272(1):182-5. PubMed ID: 10872824
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different.
Wessely R; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Feb; 47(4):708-14. PubMed ID: 16487832
[TBL] [Abstract][Full Text] [Related]
11. Potentiating effect of endothelial cells on astrocytic plasminogen activator inhibitor type-1 gene expression in an in vitro model of the blood-brain barrier.
Hultman K; Björklund U; Hansson E; Jern C
Neuroscience; 2010 Mar; 166(2):408-15. PubMed ID: 20060032
[TBL] [Abstract][Full Text] [Related]
12. Effects of two complex hemodynamic stimulation profiles on hemostatic genes in a vessel-like environment.
Bergh N; Ulfhammer E; Karlsson L; Jern S
Endothelium; 2008; 15(5-6):231-8. PubMed ID: 19065314
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1.
Chen Y; Budd RC; Kelm RJ; Sobel BE; Schneider DJ
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1777-83. PubMed ID: 16709941
[TBL] [Abstract][Full Text] [Related]
14. Endothelial cell recovery between comparator polymer-based drug-eluting stents.
Joner M; Nakazawa G; Finn AV; Quee SC; Coleman L; Acampado E; Wilson PS; Skorija K; Cheng Q; Xu X; Gold HK; Kolodgie FD; Virmani R
J Am Coll Cardiol; 2008 Jul; 52(5):333-42. PubMed ID: 18652940
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents.
Camici GG; Steffel J; Akhmedov A; Schafer N; Baldinger J; Schulz U; Shojaati K; Matter CM; Yang Z; Lüscher TF; Tanner FC
Circulation; 2006 Oct; 114(14):1512-21. PubMed ID: 17000906
[TBL] [Abstract][Full Text] [Related]
16. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
[TBL] [Abstract][Full Text] [Related]
17. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
Lüscher TF; Steffel J; Eberli FR; Joner M; Nakazawa G; Tanner FC; Virmani R
Circulation; 2007 Feb; 115(8):1051-8. PubMed ID: 17325255
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
Ota H; Eto M; Ako J; Ogawa S; Iijima K; Akishita M; Ouchi Y
J Am Coll Cardiol; 2009 Jun; 53(24):2298-305. PubMed ID: 19520256
[TBL] [Abstract][Full Text] [Related]
19. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
[TBL] [Abstract][Full Text] [Related]
20. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.
Diamond MP; Kruger M; Saed GM
Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
